Ideal: A 28-week open-label extension of a 24-week double-blind study of the first transdermal patch in Alzheimer's disease

被引：0
|
作者：
Froelich, L. [1 ]
Barone, P. [2 ]
Foerstl, H. [3 ]
Onofrj, M. [4 ]
Nagel, J.
Ros, J. [5 ]
Tekin, S. [6 ]
Orgogozo, J. [7 ]
机构：
[1] Univ Heidelberg, Cent Inst Mental Hlth, D-6800 Mannheim, Germany
[2] Univ Naples Federico 2, Naples, Italy
[3] Tech Univ Munich, D-8000 Munich, Germany
[4] Gabriele DAnnunzio Univ Fdn, Chieti, Italy
[5] Novartis Pharma AG, Basel, Switzerland
[6] Novartis Pharmaceut Corp, E Hanover, NJ USA
[7] CHU Pellegrin, Bordeaux, France
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2007年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：48 / 49
页数：2
相关论文
共 50 条
  • [21] A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of the Rivastigmine Patch in Japanese Patients with Alzheimer's Disease
    Nakamura, Yu
    Imai, Yukimichi
    Shigeta, Masahiro
    Graf, Ana
    Shirahase, Toru
    Kim, Hyosung
    Fujii, Akifumi
    Mori, Joji
    Homma, Akira
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS EXTRA, 2011, 1 (01): : 163 - 179
  • [22] Galantamine in the management of dementia with Lewy bodies: A 24-week, open-label study
    Edwards, K
    Hershey, L
    Johnson, S
    INTERNATIONAL PSYCHOGERIATRICS, 2003, 15 : 253 - 254
  • [23] Olanzapine versus ziprasidone: Results of a 28-week double-blind study in patients with schizophrenia
    Breier, A
    Berg, PH
    Thakore, JH
    Naber, D
    Gattaz, WF
    Cavazzoni, P
    Walker, DJ
    Roychowdhury, SM
    Kane, JM
    AMERICAN JOURNAL OF PSYCHIATRY, 2005, 162 (10): : 1879 - 1887
  • [24] Long-term treatment with the NMDA antagonist memantine:: Results of a 24-week, open-label extension study in moderately severe-to-severe Alzheimer's disease
    Reisberg, B
    Ferris, S
    Möbius, HJ
    Schmitt, F
    Doody, R
    NEUROBIOLOGY OF AGING, 2002, 23 (01) : S555 - S555
  • [25] Olanzapine versus ziprasidone: Results of the 28-week double-blind study in patients with schizophrenia
    Kane, JM
    Berg, P
    Thakore, J
    Naber, D
    Gattaz, WF
    Cavazzoni, P
    Walker, DJ
    Roychowdhury, SM
    Earley, W
    Breier, A
    JOURNAL OF PSYCHOPHARMACOLOGY, 2003, 17 (03) : A50 - A50
  • [26] A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease - Pilot Study
    Prasher, VP
    Huxley, A
    Haque, MS
    INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2002, 17 (03) : 270 - 278
  • [27] A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease
    Alvarez, XA
    Cacabelos, R
    Laredo, M
    Couceiro, V
    Sampedro, C
    Varela, M
    Corzo, L
    Fernandez-Novoa, L
    Vargas, M
    Aleixandre, M
    Linares, C
    Granizo, E
    Muresanu, D
    Moessler, H
    EUROPEAN JOURNAL OF NEUROLOGY, 2006, 13 (01) : 43 - 54
  • [28] A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease (vol 57, pg 613, 2001)
    Feldman, H
    Gauthier, S
    Hecker, J
    Vellas, B
    Subbiah, P
    Whalen, E
    NEUROLOGY, 2001, 57 (11) : 2153 - 2153
  • [29] A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia
    Osumokun, O.
    Kanc, J. M.
    Kryzhanovskaya, L. A.
    Xu, W.
    Stauffer, V.
    Watson, S. B.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 : 153 - 153
  • [30] A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia
    Kane, John M.
    Osuntokun, Olawale
    Kryzhanovskaya, Ludmila A.
    Xu, Wen
    Stauffer, Virginia
    Watson, Susan B.
    BIOLOGICAL PSYCHIATRY, 2008, 63 (07) : 289S - 289S
12345